Merck & Co revealed on Wednesday that it will deepen its artificial intelligence capabilities through a strategic collaboration with Google Cloud, committing up to $1 billion over multiple years to support AI infrastructure, engineering resources and licensing for Google’s Gemini Enterprise platform.
Announced at Google’s Cloud Next conference in Las Vegas, the arrangement builds on existing cooperative work between the companies and will embed Google Cloud engineers alongside Merck teams, according to executives from both organizations.
In an interview, Merck’s chief information and digital officer, Dave Williams, described the commitment in precise terms: "I easily see us investing a billion over the next several years in this, in those capabilities," he said. Williams emphasized that the spend is not intended to be limited to token purchases, adding: "We’re not just buying tokens. It is really the tool set" Google Cloud offers, including Gemini Enterprise and the company’s engineers.
Williams said the parties have not set a formal end date for the collaboration but expect it to endure. He characterized the partnership as likely to extend for at least a decade.
The companies said the partnership will work to deploy AI across Merck’s drug research, regulatory work, manufacturing and commercial operations. Both parties cast the collaboration as a means to accelerate the drug development lifecycle.
"We’ve always said we wanted AI to play a positive role in society. One of the ways is to help people find cures to illnesses," Thomas Kurian, CEO of Google Cloud, said in the same interview. "They have the domain knowledge. We’re bringing the AI tools and platform and cyber capability to help them build using these tools."
Merck intends to apply AI techniques across the drug development continuum. Williams cited examples such as running computerized simulations of laboratory experiments and accelerating regulatory processes. He noted the company has already applied AI to portions of clinical study reports for roughly two years with some success and intends to expand that application.
Williams also said Merck has leveraged Google’s technology to shorten by half both the time and cost of compiling dossiers required in many countries to obtain reimbursement for new medicines. He framed the work as operational, not experimental. "This isn’t a pilot," Williams said. "We’re submitting dossiers in markets using this new capability, and we’re now scaling it globally."
Google Cloud is a unit of Alphabet Inc.
Context and strategic emphasis
The arrangement combines Merck’s domain expertise in pharmaceuticals with Google Cloud’s AI platform and engineering resources. Executives from both companies highlighted the partnership as an extension of existing collaboration, with a focus on practical applications across regulatory filings, research simulations and manufacturing oversight.
By committing engineering resources alongside platform licensing, Merck signals an intent to integrate AI into production workflows rather than limit the technology to pilot projects.
Implications for markets and sectors
- Pharmaceuticals: Expanded AI use in drug research and regulatory processes could change operational workflows for drugmakers.
- Technology / Cloud Services: The deal underscores demand for cloud-based AI platforms and professional engineering services.
- Healthcare commercial operations: Faster dossier preparation and regulatory submissions may affect time-to-market and reimbursement processes for medicines.